Anti-mitochondrial antibodies (AMA) are directed against the E2 subunits of the 2-oxo acid
dehydrogenase complexes (PDC-E2) and are the typical biomarkers of primary biliary …

Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-
line treatment with ursodeoxycholic acid. Obeticholic acid was approved by the US Food …

Cholangiopathies encompass various biliary diseases affecting the biliary epithelium,
resulting in cholestasis, inflammation, fibrosis, and ultimately liver cirrhosis. Primary biliary …

PBC is a chronic progressive autoimmune disorder involving the destruction of intrahepatic
small bile ducts, cholestasis, fibrosis, and ultimately cirrhosis if left untreated. It is largely …

Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by
cholestasis, biliary injuries, liver fibrosis, and chronic non-suppurative cholangitis. The …

Objective The ability to regulate B cell development has long been recognized to have
therapeutic potential in a variety of autoimmune diseases. However, despite the presence of …

Background Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease
characterized by inflammation of the interlobular bile ducts. Ursodeoxycholic acid (UDCA) is …

Introduction As a common autoimmune disease with the characteristic of early complication,
primary biliary cholangitis (PBC) leads to an increasing number of mortalities among people …

Background Vaccination is the best way to protect children under 5 years from death or
disability. Children with biliary atresia (BA), which is the most common pediatric cholestatic …

Viral and alcoholic liver disease, drug induced liver disease (DILD), primary biliary cirrhosis
(PBC) and autoimmune hepatitis (AIH) are among the most common liver diseases …